Edition:
India

People: Codexis Inc (CDXS.OQ)

CDXS.OQ on NASDAQ Stock Exchange Global Select Market

14.60USD
17 Sep 2019
Change (% chg)

$-0.00 (-0.00%)
Prev Close
$14.60
Open
$14.74
Day's High
$14.79
Day's Low
$14.23
Volume
202,945
Avg. Vol
141,198
52-wk High
$23.01
52-wk Low
$12.69

Sangster, Gordon 

Mr. Gordon T. Sangster is Chief Financial Officer, Senior Vice President of the Company, effective August 18, 2014. Mr. Sangster served as Chief Financial Officer of Nitinol Devices & Components, a private medical device manufacturer, from October 2011 until July 2014. Prior to that role, Mr. Sangster was Chief Financial Officer of ITC Nexus-Dx, a private medical device company that focused on point-of-care diagnostics, from October 2010 to July 2011. From November 2007 to October 2010, Mr. Sangster was Chief Financial Officer of Micrus Endovascular, a publicly traded medical device company that was acquired by Johnson & Johnson. From 2006 to 2007, Mr. Sangster was also Chief Financial Officer of HemoSense, Inc., a publicly traded medical device company that was acquired by Alere. Prior to that role, Mr. Sangster was Chief Financial Officer of AP Pharma, a publicly traded biotechnology company, from 2000 to 2006. Prior to his Chief Financial Officer roles, Mr. Sangster held roles of increasing responsibility in finance at AP Pharma, Raychem, and CooperVision. Mr. Sangster is a member of the Institute of Chartered Accountants in England and Wales.

Basic Compensation

Total Annual Compensation, USD 608,400
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 790,538
Fiscal Year Total, USD 1,398,940

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised 80,000 1,158,990.00
Name Fiscal Year Total

Bernard Kelley

204,995

John Nicols

3,438,810

Gordon Sangster

1,398,940

Laurie Heilmann

--

Thomas Baruch

154,995

Pam Cheng

169,995
As Of  31 Dec 2018